Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of their principal into common shares at $0.32 per share, resulting in the issuance of 4,375,000 common shares. This conversion represents 35% of the Company's previously outstanding debenture principal of $4 million, significantly strengthening its balance sheet as it advances toward key milestones in its ongoing patient study program.
The conversion of debt into equity is expected to improve the Company's financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of Ocumetics' technology platform and clinical development objectives. The Company continues to prepare for its planned Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration, marking a critical regulatory step.
"These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision," said Dean Burns, President and CEO of Ocumetics. "We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company."
Ocumetics is developing a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is intended to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses. The Company is currently in the first-in-human early feasibility study phase, a game-changing technology for the ophthalmic industry.
With a stronger balance sheet and reduced debt, Ocumetics is better positioned to fund its clinical development and regulatory activities. The conversion aligns debtholders with equity investors, reducing financial risk and interest obligations as the Company progresses toward commercialization. The next major milestones include patient study updates and the IDE submission, which could pave the way for broader clinical trials in the United States.
The Company's technology aims to address a significant unmet need in vision correction, offering a potential alternative to glasses, contact lenses, and laser surgery. By leveraging the eye's natural focusing mechanism, the Ocumetics lens could provide a more natural visual experience across all distances. Successful clinical outcomes could disrupt the intraocular lens market and improve quality of life for millions of patients.
For further information, interested parties can visit the original release at NewMediaWire.
